K. Oettel

发表

A morphealike skin condition caused by Borrelia burgdorferi in an immunocompromised patient.

J. Sartin, K. Oettel, 2006, Mayo Clinic proceedings.

Characterization of cytokine, growth factor receptor, costimulatory and adhesion molecule expression patterns of bone marrow blasts in relapsed childhood B cell precursor all.

K. Seeger, A. Möricke, J. Köchling, 2001, Cytokine.

Characteristics and outcome of patients with active pulmonary tuberculosis requiring intensive care

H. Lode, H. Mauch, R. Erbes, 2006, European Respiratory Journal.

Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer

R. Mazess, G. Wilding, R. Bruskewitz, 2002 .

Vorinostat and bortezomib as third-line therapy in patients with advanced non-small cell lung cancer: a Wisconsin Oncology Network Phase II study

J. Kolesar, KyungMann Kim, T. Campbell, 2014, Investigational New Drugs.

A Review of Concurrent Chemo/Radiation, Immunotherapy, Radiation Planning, and Biomarkers for Locally Advanced Non-small Cell Lung Cancer and Their Role in the Development of ECOG-ACRIN EA5181.

C. Lovly, M. Harkenrider, N. Pennell, 2022, Clinical lung cancer.

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

G. Wilding, D. Alberti, K. M. Kim, 2006, Investigational New Drugs.

MHC-UNRESTRICTED CYTOTOXIC AND PROLIFERATIVE RESPONSES OF TWO DISTINCT HUMAN y / 6 TCELL SUBSETS TO DAUDI CELLS '

Paul, P. Sondel, M. Malkovský, 2009 .

A Review of Immunotherapy for Stage III and Metastatic Non-Small Cell Lung Cancer and the Rationale for the ECOG-ACRIN EA5181 Study

Katz, H. Wakelee, M. Diehn, 2021 .

Specific recognition of human leukemic cells by allogeneic T cell lines.

J. Sosman, P. Fisch, J. Hank, 1989, Transplantation.

Phase I trial of 1alpha-hydroxyvitamin d(2) in patients with hormone refractory prostate cancer.

R. Mazess, G. Wilding, R. Bruskewitz, 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

Allogeneic T-cell clones able to selectively destroy Philadelphia chromosome-bearing (Ph1+) human leukemia lines can also recognize Ph1- cells from the same patient.

J. Sosman, K. Voelkerding, M. Albertini, 1994, Blood.

cells crossreactive with determinants present on unrelated nonleukemic Evidence for HLA-D restricted determinants on leukemic cells that are Specific recognition of human leukemic cells by allogeneic T cells: II.

J. Sosman, P. Fisch, J. Hank, 2016 .

Specific recognition of human leukemic cells by allogeneic T cells: II. Evidence for HLA-D restricted determinants on leukemic cells that are crossreactive with determinants present on unrelated nonleukemic cells.

S. Smith, J. Sosman, P. Fisch, 1990, Blood.

Effect of medical castration on CYP3A4 enzyme activity using the erythromycin breath test

M. Ritter, G. Wilding, P. Hutson, 2008, Cancer Chemotherapy and Pharmacology.

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

J. Manola, S. Lonial, A. Dueck, 2018, Blood Cancer Journal.

Phase I/II Study of Gemcitabine and Exisulind as Second-Line Therapy in Patients with Advanced Non–small Cell Lung Cancer

T. Hensing, KyungMann Kim, J. Schiller, 2006, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II trial of perillyl alcohol (NSC 641066) administered daily in patients with metastatic androgen independent prostate cancer

D. DeMets, G. Wilding, H. Bailey, 2003, Investigational New Drugs.

MHC-unrestricted cytotoxic and proliferative responses of two distinct human gamma/delta T cell subsets to Daudi cells.

P. Fisch, P. Sondel, M. Malkovský, 1992, Journal of immunology.

A review of immunotherapy for stage 3 and metastatic NSCLC & the rationale for the ECOG-ACRIN EA5181 study.

Sharyn I. Katz, D. Mankoff, H. Wakelee, 2021, The oncologist.

American Society of Clinical Oncology Road to Recovery Report: Learning From the COVID-19 Experience to Improve Clinical Research and Cancer Care.

Jonathan M Marron, Laura A. Levit, R. Schilsky, 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I/II Study of Vinorelbine and Exisulind as First-Line Treatment of Advanced Non-small Cell Lung Cancer in Patients at Least 70 Years Old: A Wisconsin Oncology Network Study

KyungMann Kim, J. Schiller, G. Masters, 2008, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

A phase I study of sorafenib, oxaliplatin and 2 days of high dose capecitabine in advanced pancreatic and biliary tract cancer: a Wisconsin oncology network study

D. Deming, T. Goggins, S. Lubner, 2013, Investigational New Drugs.

Cetuximab plus carboplatin and paclitaxel with or without bevacizumab versus carboplatin and paclitaxel with or without bevacizumab in advanced NSCLC (SWOG S0819): a randomised, phase 3 study.

Susanne M Arnold, Mary W Redman, Karen Kelly, 2018, The Lancet. Oncology.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

Lenalidomide and dexamethasone in patients with relapsed multiple myeloma and impaired renal function: PrE1003, a PrECOG study

J. Manola, S. Lonial, A. Dueck, 2018, Blood Cancer Journal.

Are We on the Same Page? Patient and Provider Perceptions About Exercise in Cancer Care: A Focus Group Study.

A. Borgert, K. Oettel, A. Smáradóttir, 2017, Journal of the National Comprehensive Cancer Network : JNCCN.

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

H. Wakelee, S. Ramalingam, C. Lovly, 2021 .

Benchmarks for Academic Oncology Faculty.

P. Kantoff, J. Vose, L. Carey, 2020, JCO oncology practice.

Nuclear EGFR protein expression predicts poor survival in early stage non-small cell lung cancer.

R. Salgia, KyungMann Kim, D. Wheeler, 2013, Lung cancer.

Vorinostat (V) and bortezomib (B) as third-line treatment in patients with advanced non-small cell lung cancer (NSCLC): A Wisconsin Oncology Network Phase II Study.

J. Kolesar, M. Jones, T. Campbell, 2011, Journal of Clinical Oncology.

timeliness of Lung cancer care: Assessing the needs and Measuring outcomes using Patient Interviews

Marianna B. Shershneva, T. Campbell, K. Oettel, 2013 .

L. Bazhenova, P. Mack, M. Redman, 2017 .